| 2.01 -0.29 (-12.61%) | 12-15 15:39 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.18 |
1-year : | 3.76 |
| Resists | First : | 2.73 |
Second : | 3.22 |
| Pivot price | 2.56 |
|||
| Supports | First : | 1.94 |
Second : | 1.61 |
| MAs | MA(5) : | 2.43 |
MA(20) : | 2.5 |
| MA(100) : | 3.02 |
MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 11.4 |
D(3) : | 29.3 |
| RSI | RSI(14): 36.1 |
|||
| 52-week | High : | 88.4 | Low : | 1.94 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ONCO ] has closed above bottom band by 0.8%. Bollinger Bands are 13.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.31 - 2.33 | 2.33 - 2.34 |
| Low: | 2.26 - 2.28 | 2.28 - 2.29 |
| Close: | 2.28 - 2.3 | 2.3 - 2.32 |
Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Wed, 10 Dec 2025
Onconetix Approves CEO Bonus and Stockholder Proposals - TipRanks
Wed, 10 Dec 2025
Onconetix Amends License Agreement with Labcorp - TipRanks
Fri, 26 Sep 2025
Breaking: $2.1B Biotech Merger Collapses - Onconetix and Ocuvex Part Ways as Ocuvex Preps Drug Launch - Stock Titan
Wed, 16 Jul 2025
Onconetix to buy privately held Ocuvex Therapeutics (ONCO) - Seeking Alpha
Wed, 16 Jul 2025
Onconetix and Ocuvex Therapeutics announce definitive merger agreement - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 1.26e+006 (%) |
| Held by Institutions | 19.5 (%) |
| Shares Short | 125 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -681.5 % |
| Return on Assets (ttm) | -7.5 % |
| Return on Equity (ttm) | -221.4 % |
| Qtrly Rev. Growth | -25.4 % |
| Gross Profit (p.s.) | 307018 |
| Sales Per Share | 356725 |
| EBITDA (p.s.) | -1.37427e+006 |
| Qtrly Earnings Growth | 229.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | 2 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 3.18 |
| Dividend | 0 |
| Forward Dividend | 66360 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|